Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

Severe hypoglycaemia (SH) remains a challenge to people with type 1 diabetes (T1DM), and new‐generation basal insulins may improve patient outcomes. This post hoc meta‐analysis explored the risk of SH with insulin glargine 300 U/mL (Gla‐300) versus glargine 100 U/mL (Gla‐100) in a pooled population...

Descripción completa

Detalles Bibliográficos
Autores principales: Danne, Thomas, Matsuhisa, Munehide, Sussebach, Christian, Goyeau, Harmonie, Lauand, Felipe, Niemoeller, Elisabeth, Bolli, Geremia B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540568/
https://www.ncbi.nlm.nih.gov/pubmed/32515543
http://dx.doi.org/10.1111/dom.14109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540568/
https://www.ncbi.nlm.nih.gov/pubmed/32515543
http://dx.doi.org/10.1111/dom.14109

Ejemplares similares